+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Regenerative Medicine Market - Global Forecast 2026-2032- Product Image
Regenerative Medicine Market - Global Forecast 2026-2032- Product Image
Sale

Regenerative Medicine Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4857893
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Regenerative Medicine Market is projected to reach USD 36.39 Billion in 2026. It is expected to continue growing at a CAGR of 21.64%, reaching USD 118.33 Billion by 2032.

Regenerative medicine is moving from experimental promise to a regulated, evidence-driven healthcare category spanning cell therapy, gene therapy, tissue engineering, stem cell therapy, biomaterials, extracellular vesicle platforms, and advanced wound-repair technologies. The field is being shaped by authorized advanced therapies, expanding clinical-trial pipelines, and stronger manufacturing standards under agencies such as the U.S. FDA, European Medicines Agency, Japan’s PMDA, and other national regulators.

Demand is supported by the clinical burden of cancer, rare genetic disorders, musculoskeletal injuries, cardiovascular disease, diabetes, neurodegenerative conditions, and chronic wounds. Industry momentum is increasingly tied to scalable GMP manufacturing, durable clinical outcomes, real-world evidence, cold-chain logistics, reimbursement readiness, and the ability to convert biological innovation into reproducible, patient-accessible therapies.

Transformative Shifts in the Regenerative Medicine Landscape

The regenerative medicine landscape is shifting from bespoke, single-site development toward industrialized platforms. Autologous CAR-T therapies demonstrated the clinical and commercial potential of engineered cells, while allogeneic cell therapy, in vivo gene editing, induced pluripotent stem cell platforms, extracellular vesicle therapeutics, and 3D bioprinting are reshaping expectations for scalability, consistency, and repeatability.

Regulatory pathways are also maturing. Accelerated designations, hospital exemption models, ATMP rules in Europe, and regenerative medicine advanced therapy pathways in the United States are helping sponsors align evidence generation with patient access. At the same time, regulators are intensifying oversight of unproven stem cell interventions, making validated potency assays, traceable supply chains, standardized release criteria, and long-term safety monitoring critical differentiators.

Cumulative Impact of Artificial Intelligence in Regenerative Medicine

Artificial intelligence is becoming a cumulative force across regenerative medicine research, development, manufacturing, and commercialization. AI-enabled analytics support target discovery, vector design, cell phenotype prediction, donor selection, image-based quality control, biomarker identification, and preclinical model interpretation, helping developers shorten iteration cycles while improving reproducibility.

The largest impact is emerging in manufacturing and clinical evidence generation. Machine learning can detect batch variability, predict process deviations, optimize bioreactor conditions, and support digital release testing. In clinical programs, AI helps stratify patients, analyze multimodal outcomes, identify safety signals, and strengthen real-world evidence; however, adoption must remain aligned with data integrity, model validation, privacy, cybersecurity, and explainability requirements.

Key Regional Insights: Global Regenerative Medicine Adoption

North America remains a leading region for regenerative medicine because of FDA oversight, deep biomedical financing, academic medical centers, specialized contract development and manufacturing capacity, and early adoption of cell and gene therapies. The United States anchors clinical translation through advanced therapy designations, treatment-center networks, and biomanufacturing investment, while Canada contributes through stem cell research networks, public-private biomanufacturing initiatives, and hospital-based innovation.

Europe is characterized by the European Medicines Agency’s advanced therapy medicinal product framework, strong public research funding, and established biopharma clusters across Germany, France, Italy, Spain, and the United Kingdom. The region benefits from coordinated clinical research, transplantation expertise, and structured pharmacovigilance requirements, although access pathways and reimbursement decisions remain country-specific. Asia-Pacific is advancing rapidly through Japan’s conditional and time-limited approval environment for regenerative medical products, China’s large clinical-trial base, South Korea’s cell therapy expertise, India’s expanding biomanufacturing capacity, and Australia’s translational research infrastructure.

Latin America is gaining relevance through Brazil and Mexico, where specialized hospitals, oncology needs, academic cell therapy research, and local manufacturing ambitions are driving interest. The Middle East is investing in precision medicine, genomics, and advanced healthcare infrastructure, particularly across GCC markets that are building specialized care models. Africa remains earlier-stage but presents long-term opportunity in regenerative wound care, sickle cell disease, burn treatment, and capacity-building partnerships supported by clinical training, ethical governance, and sustainable supply chains.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are strengthening regenerative medicine through medical tourism, hospital modernization, biomanufacturing interest, and growing demand for cell therapy services, with Singapore providing a regional hub for biomedical regulation, translational research, and clinical innovation. The GCC is positioning regenerative medicine within national healthcare transformation agendas, supported by specialist hospitals, genomics programs, digital health infrastructure, and investment in advanced therapy capabilities.

The European Union offers one of the most defined regulatory environments through ATMP governance, centralized marketing authorization, clinical-trial harmonization, pharmacovigilance obligations, and cross-border research funding. BRICS countries provide scale, patient diversity, and manufacturing potential, with China, India, and Brazil especially important for clinical development, local production, and cost-efficient process innovation. G7 markets remain central to reimbursement standards, intellectual property protection, clinical guideline development, and premium therapy adoption, while NATO-aligned economies contribute through resilient supply chains, biomedical security priorities, and harmonized research collaboration for advanced therapeutic platforms.

Key Country Insights: Priority Regenerative Medicine Markets

The United States leads commercialization through FDA-authorized cell and gene therapies, specialized treatment centers, advanced clinical-trial infrastructure, and a strong biotechnology ecosystem. Canada supports regenerative medicine through national research networks, stem cell science, and advanced manufacturing initiatives, while Mexico is developing capacity around specialty care, transplantation expertise, and cross-border healthcare demand. Brazil is Latin America’s most visible regenerative medicine market, supported by academic hospitals, public research institutions, cell therapy studies, and a large patient base with high unmet need.

In Europe, the United Kingdom remains a translational leader with strong clinical-trial infrastructure and advanced therapy manufacturing programs; Germany combines engineering, biologics manufacturing, hospital depth, and regulatory discipline; France benefits from public research and biotherapy expertise; Italy and Spain contribute through ATMP clinical networks, transplantation experience, and specialist hospitals; and Russia maintains scientific activity in cell therapy and biomedical research despite geopolitical constraints affecting international collaboration and supply access.

In Asia-Pacific, China has one of the world’s most active cell and gene therapy pipelines, supported by hospital-led research, regulatory reforms, and domestic manufacturing capabilities. India is expanding affordable biomanufacturing, stem cell research, and specialty clinical services under evolving regulatory supervision. Japan benefits from a supportive regenerative medicine framework and strong iPSC science, Australia provides high-quality translational research and clinical governance, and South Korea remains a major innovator in stem cell therapy, cell processing, and advanced therapy commercialization.

Actionable Recommendations for Regenerative Medicine Leaders

Industry leaders should prioritize platform scalability over single-asset development by investing in closed-system manufacturing, validated potency assays, automated quality control, standardized comparability protocols, and fit-for-purpose cold-chain networks. Early engagement with regulators and payers is essential to align trial endpoints, durability evidence, companion diagnostics, patient follow-up, and post-authorization commitments with access requirements.

Organizations should also build AI governance, data interoperability, model validation, and cybersecurity into development programs from the outset. Partnerships with academic medical centers, contract manufacturers, hospitals, donor networks, and patient registries can accelerate recruitment and real-world evidence generation. Commercial strategies should include value-based contracting, site-of-care readiness, clinician education, transparent patient safety communication, and clear evidence plans for long-term outcomes.

Research Methodology

Research methodology is grounded in secondary research from regulatory guidance, clinical-trial registries, peer-reviewed literature, health agency publications, patent activity, reimbursement updates, scientific society materials, and recognized industry databases. Findings were synthesized to identify demand drivers, technology shifts, regional dynamics, competitive priorities, manufacturing constraints, evidence requirements, and commercialization barriers across regenerative medicine modalities.

The methodology emphasizes triangulation across scientific, regulatory, and commercial sources. Market signals were evaluated through therapy modality, clinical maturity, manufacturing readiness, geographic adoption, policy environment, quality-control expectations, and evidence-generation requirements. Insights were reviewed for consistency with verified public information and are presented in a leader-focused format for strategic decision-making without relying on market sizing, market share, or forecasting.

Conclusion

Regenerative medicine is entering a decisive phase in which scientific breakthroughs must be matched with manufacturing discipline, regulatory credibility, ethical governance, and payer confidence. Cell therapy, gene therapy, tissue engineering, stem cell therapy, extracellular vesicles, and biomaterials are converging into a broader advanced-therapy ecosystem focused on durable outcomes, personalized care, and restoration of biological function.

Organizations that combine validated science, AI-enabled operations, scalable production, robust real-world evidence, and transparent safety monitoring will be best positioned to capture opportunity in regenerative medicine. The next stage will favor developers that move beyond innovation narratives and deliver safe, reproducible, accessible, and clinically meaningful regenerative therapies for patients with high unmet medical need.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Regenerative Medicine Market, by Product Type
7.1. Introduction
7.2. Cell Therapy
7.2.1. Non-Stem Cell-Based Therapy
7.2.1.1. Immune Cells
7.2.1.1.1. Dendritic Cells
7.2.1.1.2. Natural Killer (NK) Cells
7.2.1.1.3. T Cells
7.2.1.2. Non-immune Cells
7.2.2. Stem Cell-Based Therapy
7.3. Extracellular & Acellular Therapies
7.4. Gene Therapy
7.4.1. Gene Editing Technologies
7.4.2. Gene Transfer Vectors
7.4.2.1. Non-Viral Vectors
7.4.2.2. Viral Vectors
7.4.3. RNA & DNA-Based Therapies
7.5. Tissue Engineering
7.5.1. Biomaterials
7.5.1.1. Natural Biomaterials
7.5.1.2. Synthetic Biomaterials
7.5.2. Growth Factors & Cytokines
7.5.3. Scaffolds
8. Regenerative Medicine Market, by Source
8.1. Introduction
8.2. Allogeneic
8.3. Autologous
8.4. Synthetic
9. Regenerative Medicine Market, by Application Areas
9.1. Introduction
9.2. Cardiovascular
9.2.1. Angiogenesis & Vascular Regeneration
9.2.2. Congenital Heart Defect Repair
9.2.3. Heart Valve Replacement
9.2.4. Myocardial Infarction Treatment
9.3. Dermatology
9.3.1. Aesthetic Procedures
9.3.2. Burn Treatment
9.3.3. Chronic Wound Healing
9.4. Diabetes
9.4.1. Beta Cell Transplantation
9.4.2. Islet Cell Regeneration
9.5. Neurology
9.5.1. Alzheimer's Treatment
9.5.2. Multiple Sclerosis Therapy
9.5.3. Parkinson's Therapy
9.5.4. Spinal Cord Injury Repair
9.5.5. Stroke Recovery
9.6. Oncology
9.6.1. Cancer Immunotherapy
9.6.2. Tumor Ablation
9.7. Ophthalmology
9.7.1. Corneal Repair
9.7.2. Retinal Regeneration
9.8. Orthopedic & Musculoskeletal
9.8.1. Bone Regeneration
9.8.2. Cartilage Repair
9.8.3. Tendon Repair
10. Regenerative Medicine Market, by End User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Contract Research Organizations
10.4. Hospitals & Clinics
10.5. Pharmaceutical & Biotechnology Companies
11. Regenerative Medicine Market, by Region
11.1. North America
11.2. Asia-Pacific
11.3. Europe
11.4. Latin America
11.5. Middle East
11.6. Africa
12. Regenerative Medicine Market, by Group
12.1. NATO
12.2. G7
12.3. BRICS
12.4. European Union
12.5. ASEAN
12.6. GCC
13. Regenerative Medicine Market, by Country
13.1. United States
13.2. China
13.3. Japan
13.4. Canada
13.5. Germany
13.6. India
13.7. Mexico
13.8. France
13.9. United Kingdom
13.10. Brazil
13.11. Australia
13.12. Italy
13.13. South Korea
13.14. Russia
13.15. Spain
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Novartis AG
15.2. Gilead Sciences, Inc.
15.3. Stryker Corporation
15.4. Johnson & Johnson Services, Inc.
15.5. FUJIFILM Holdings Corporation
15.6. Zimmer Biomet Holdings, Inc.
15.7. Merck KGaA
15.8. Integra LifeSciences Holdings Corporation
15.9. AbbVie Inc.
15.10. F. Hoffmann-La Roche Ltd.
15.11. AGC Inc.
15.12. Organogenesis Holdings Inc.
15.13. CRISPR Therapeutics AG
15.14. CMIC HOLDINGS Co., LTD.
15.15. JCR Pharmaceuticals Co., Ltd.
15.16. Sysmex Corporation
15.17. Vericel Corporation
15.18. Orchard Therapeutics PLC
15.19. STEMPEUTICS RESEARCH PVT LTD
15.20. REPROCELL Inc.
15.21. Mesoblast Limited
15.22. 4D Molecular Therapeutics, Inc.
15.23. Abeona Therapeutics Inc.
15.24. Astellas Pharma Inc.
15.25. Athersys, Inc.
15.26. Bayer AG
15.27. Fate Therapeutics, Inc.
15.28. NervGen Pharma Corp.
15.29. Pluri Biotech Ltd.
15.30. Regentis Biomaterials Ltd.
15.31. RepliCel Life Sciences Inc.
15.32. SanBio Co,Ltd.
15.33. SMSbiotech, Inc.
15.34. Sumitomo Pharma Co., Ltd.
15.35. Tenaya Therapeutics, Inc.
15.36. Voyager Therapeutics Inc.
List of Figures
FIGURE 1. GLOBAL REGENERATIVE MEDICINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL REGENERATIVE MEDICINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL REGENERATIVE MEDICINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL REGENERATIVE MEDICINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL NON-STEM CELL-BASED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL NON-STEM CELL-BASED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL NON-STEM CELL-BASED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNE CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNE CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNE CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL DENDRITIC CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL DENDRITIC CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL DENDRITIC CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL NATURAL KILLER (NK) CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL NATURAL KILLER (NK) CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL NATURAL KILLER (NK) CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL T CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL NON-IMMUNE CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NON-IMMUNE CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NON-IMMUNE CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL STEM CELL-BASED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL STEM CELL-BASED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL STEM CELL-BASED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL EXTRACELLULAR & ACELLULAR THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL EXTRACELLULAR & ACELLULAR THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL EXTRACELLULAR & ACELLULAR THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL GENE TRANSFER VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL GENE TRANSFER VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL GENE TRANSFER VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL RNA & DNA-BASED THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL RNA & DNA-BASED THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL RNA & DNA-BASED THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TISSUE ENGINEERING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BIOMATERIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BIOMATERIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL BIOMATERIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL NATURAL BIOMATERIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL NATURAL BIOMATERIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL NATURAL BIOMATERIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SYNTHETIC BIOMATERIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SYNTHETIC BIOMATERIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SYNTHETIC BIOMATERIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL GROWTH FACTORS & CYTOKINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL GROWTH FACTORS & CYTOKINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL GROWTH FACTORS & CYTOKINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SCAFFOLDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SCAFFOLDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SCAFFOLDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ANGIOGENESIS & VASCULAR REGENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ANGIOGENESIS & VASCULAR REGENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ANGIOGENESIS & VASCULAR REGENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CONGENITAL HEART DEFECT REPAIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CONGENITAL HEART DEFECT REPAIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CONGENITAL HEART DEFECT REPAIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HEART VALVE REPLACEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HEART VALVE REPLACEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HEART VALVE REPLACEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL MYOCARDIAL INFARCTION TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL AESTHETIC PROCEDURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL AESTHETIC PROCEDURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL AESTHETIC PROCEDURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL BURN TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL BURN TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL BURN TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL CHRONIC WOUND HEALING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL CHRONIC WOUND HEALING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL CHRONIC WOUND HEALING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL BETA CELL TRANSPLANTATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL BETA CELL TRANSPLANTATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL BETA CELL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ISLET CELL REGENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ISLET CELL REGENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ISLET CELL REGENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ALZHEIMER'S TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ALZHEIMER'S TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ALZHEIMER'S TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL MULTIPLE SCLEROSIS THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL MULTIPLE SCLEROSIS THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL MULTIPLE SCLEROSIS THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL PARKINSON'S THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL PARKINSON'S THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL PARKINSON'S THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL SPINAL CORD INJURY REPAIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL SPINAL CORD INJURY REPAIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL SPINAL CORD INJURY REPAIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL STROKE RECOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL STROKE RECOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL STROKE RECOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL TUMOR ABLATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL CORNEAL REPAIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL CORNEAL REPAIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL CORNEAL REPAIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL RETINAL REGENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL RETINAL REGENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL RETINAL REGENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL ORTHOPEDIC & MUSCULOSKELETAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL ORTHOPEDIC & MUSCULOSKELETAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL ORTHOPEDIC & MUSCULOSKELETAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL BONE REGENERATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL BONE REGENERATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL BONE REGENERATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL CARTILAGE REPAIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL TENDON REPAIR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL TENDON REPAIR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL TENDON REPAIR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 179. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 195. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 196. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 197. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 198. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 199. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 200. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 201. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 215. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 216. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 217. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 218. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 219. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 220. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 221. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 222. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 223. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 224. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 225. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 226. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 227. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 228. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 229. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 230. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 231. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 232. EUROPE REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 233. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 234. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 235. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 236. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 237. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 238. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 239. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 240. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 241. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 242. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 243. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 244. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 245. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 246. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 247. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 248. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 249. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 250. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 251. LATIN AMERICA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 259. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 260. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 261. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 262. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 263. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 264. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 265. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 266. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 267. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 268. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 269. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 270. MIDDLE EAST REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 272. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 273. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 274. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 275. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 276. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 277. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 278. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 279. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 280. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 281. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 282. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 283. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 284. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 285. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 286. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 287. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 288. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 289. AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 291. NATO REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 292. NATO REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 293. NATO REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 294. NATO REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 295. NATO REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 296. NATO REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 297. NATO REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 298. NATO REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 299. NATO REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 300. NATO REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 301. NATO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 302. NATO REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 303. NATO REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 304. NATO REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 305. NATO REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 306. NATO REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 307. NATO REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 308. NATO REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 309. NATO REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. G7 REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 311. G7 REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 312. G7 REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 313. G7 REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 314. G7 REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 315. G7 REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 316. G7 REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 317. G7 REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 318. G7 REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 319. G7 REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 320. G7 REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 321. G7 REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 322. G7 REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 323. G7 REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 324. G7 REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 325. G7 REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 326. G7 REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 327. G7 REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 328. G7 REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 330. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 331. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 332. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 333. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 334. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 335. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 336. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 337. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 338. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 339. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2017-2032 (USD MILLION)
TABLE 340. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 341. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2017-2032 (USD MILLION)
TABLE 342. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2017-2032 (USD MILLION)
TABLE 343. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2017-2032 (USD MILLION)
TABLE 344. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 345. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2017-2032 (USD MILLION)
TABLE 346. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2017-2032 (USD MILLION)
TABLE 347. BRICS REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 348. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 349. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 350. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2017-2032 (USD MILLION)
TABLE 351. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2017-2032 (USD MILLION)
TABLE 352. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2017-2032 (USD MILLION)
TABLE 353. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 354. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2017-2032 (USD MILLION)
TABLE 355. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2017-2032 (USD MILLION)
TABLE 356. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2017-2032 (USD MILLION)
TABLE 357. EUROPEAN UNION REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2017-2032 (USD MILLION)
TABLE 358.

Companies Mentioned

  • Novartis AG
  • Gilead Sciences, Inc.
  • Stryker Corporation
  • Johnson & Johnson Services, Inc.
  • FUJIFILM Holdings Corporation
  • Zimmer Biomet Holdings, Inc.
  • Merck KGaA
  • Integra LifeSciences Holdings Corporation
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • AGC Inc.
  • Organogenesis Holdings Inc.
  • CRISPR Therapeutics AG
  • CMIC HOLDINGS Co., LTD.
  • JCR Pharmaceuticals Co., Ltd.
  • Sysmex Corporation
  • Vericel Corporation
  • Orchard Therapeutics PLC
  • STEMPEUTICS RESEARCH PVT LTD
  • REPROCELL Inc.
  • Mesoblast Limited
  • 4D Molecular Therapeutics, Inc.
  • Abeona Therapeutics Inc.
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Bayer AG
  • Fate Therapeutics, Inc.
  • NervGen Pharma Corp.
  • Pluri Biotech Ltd.
  • Regentis Biomaterials Ltd.
  • RepliCel Life Sciences Inc.
  • SanBio Co,Ltd.
  • SMSbiotech, Inc.
  • Sumitomo Pharma Co., Ltd.
  • Tenaya Therapeutics, Inc.
  • Voyager Therapeutics Inc.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 36.39 Billion
Forecasted Market Value ( USD ) by 2032 $ 118.33 Billion
Compound Annual Growth Rate21.6%
Regions CoveredGlobal
No. of Companies Mentioned36

Related Topics

Related Reports

Translational Regenerative Medicine Market - Global Forecast 2026-2032 - Product Image

Translational Regenerative Medicine Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Artificial Intelligence in Regenerative Medicine Market - Global Forecast 2026-2032 - Product Image

Artificial Intelligence in Regenerative Medicine Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Regenerative Medicine Market Report by Type, Application, End User, and Region 2026-2034 - Product Image

Regenerative Medicine Market Report by Type, Application, End User, and Region 2026-2034

  • Report
  • 147 Pages
  • Global
From
Regenerative Medicine for Cartilage Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Regenerative Medicine for Cartilage Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Regenerative Medicine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Regenerative Medicine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From

About the Regenerative Medicine Market

Regenerative Medicine is a field of biotechnology that focuses on the development of treatments and therapies that can restore or replace damaged or diseased cells, tissues, and organs. It is based on the principles of stem cell biology, tissue engineering, and gene therapy. It has the potential to revolutionize the way diseases are treated, and to improve the quality of life for patients. Regenerative Medicine is a rapidly growing field, with a wide range of applications. It is being used to treat a variety of conditions, including cardiovascular diseases, neurological disorders, and musculoskeletal injuries. It is also being used to develop treatments for cancer, diabetes, and other chronic diseases. Some of the companies in the Regenerative Medicine market include Athersys, Inc., Celgene Corporation, Osiris Therapeutics, Inc., Vericel Corporation, and Organogenesis, Inc. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.